News Shortcuts from other journals

Meta-analysis confirms rosiglitazone's poor safety record

BMJ 2007; 335 doi: (Published 20 September 2007) Cite this as: BMJ 2007;335:586

Rosiglitazone is still approved by the US Food and Drugs Administration (FDA) for the treatment of type 2 diabetes, despite evidence from meta-analyses that it is associated with an increased risk of heart attack and heart failure.

A third meta-analysis, this time …

View Full Text

Log in

Log in through your institution


* For online subscription